This Article Full Text Full Text (PDF) All Versions of this Article: 108/1/67    most recent 01.CIR.0000078640.59296.6Fv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Russo, A. M. Articles by Buxton, A. E. Search for Related Content PubMed PubMed Citation Articles by Russo, A. M. Articles by Buxton, A. E. Related Collections Primary prevention Arrhythmias, clinical electrophysiology, drugs

(Circulation. 2003;108:67.)
© 2003 American Heart Association, Inc.

Clinical Investigation and Reports

Racial Differences in Outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT)

A Comparison of Whites Versus Blacks

Andrea M. Russo, MD; Gail E. Hafley, MS; Kerry L. Lee, PhD; Nicholas J. Stamato, MD; Michael H. Lehmann, MD; Richard L. Page, MD; Teresa Kus, MD, PhD; Alfred E. Buxton, MD, and the MUSTT Investigators

From the University of Pennsylvania Health System, Philadelphia (A.M.R.); Duke University (G.E.H., K.L.L.), Durham, NC; SUNY Upstate Medical University (N.J.S.), Syracuse, NY; University of Michigan Health System (M.H.L.), Ann Arbor, Mich; University of Texas Southwestern Medical Center at Dallas (R.L.P.); Hospital du Sacre-Coeur (T.K.), Montreal, Quebec, Canada; Brown Medical School (A.E.B.), Providence, Rhode Island; and the Multicenter UnSustained Tachycardia Trial (MUSTT) Investigators.

Correspondence to Andrea M. Russo, MD, University of Pennsylvania Health System, Presbyterian Medical Center, 4th Floor PHI, 38th and Market Streets, Philadelphia, PA 19104. E-mail andrea_russo{at}uphs.upenn.edu

Background— The Multicenter UnSustained Tachycardia Trial (MUSTT) demonstrated the benefit of implantable cardioverter-defibrillators (ICDs) in patients with coronary disease, asymptomatic nonsustained ventricular tachycardia, and reduced left ventricular function. Previous studies have shown racial differences in risk of sudden death in patients with ischemic heart disease.

Methods and Results— We analyzed the influence of race on results of MUSTT. Whites were more likely to have prior revascularization and inducible, randomizable sustained ventricular arrhythmias and less likely to have left ventricular hypertrophy than were blacks. Compared with blacks, whites randomly assigned to electrophysiologically (EP)-guided therapy had a lower risk of arrhythmic death/cardiac arrest (adjusted P=0.003) and lower total mortality rates (adjusted P=0.051). In contrast, there was no racial difference in the risk of arrhythmic death/cardiac arrest among patients randomly assigned to no EP-guided therapy (adjusted P=0.477). Among whites, EP-guided therapy resulted in a survival benefit compared with no EP-guided therapy. However, survival of blacks randomly assigned to no EP-guided therapy was better than blacks receiving EP-guided therapy. This difference is partially explained by a higher ICD implantation rate in whites versus blacks (50% versus 28%, P=0.034). Whites were more likely to remain inducible after serial EP-guided drug testing (67% versus 42%, P=0.011), making them more likely to become eligible for ICDs.

Conclusions— The outcome in this trial and the benefit of EP-guided therapy appeared to be influenced by race. In addition to differences in ICD implantation rates, differences in arrhythmic substrates and proarrhythmic responses to antiarrhythmic drugs may have influenced outcome.

Key Words: arrhythmia • coronary disease • death, sudden • tachycardia

This article has been cited by other articles:

				A. P. Kalogeropoulos, V. V. Georgiopoulou, G. Giamouzis, A. L. Smith, S. A. Agha, S. Waheed, S. Laskar, J. Puskas, S. Dunbar, D. Vega, et al. Utility of the Seattle heart failure model in patients with advanced heart failure. J. Am. Coll. Cardiol., January 27, 2009; 53(4): 334 - 342. [Abstract] [Full Text] [PDF]

				A. Voigt, R. Ezzeddine, W. Barrington, O. Obiaha-Ngwu, L. I. Ganz, B. London, and S. Saba Utilization of implantable cardioverter-defibrillators in survivors of cardiac arrest in the United States from 1996 to 2001 J. Am. Coll. Cardiol., August 18, 2004; 44(4): 855 - 858. [Abstract] [Full Text] [PDF]

				D. G Katritsis and A.J. Camm Nonsustained ventricular tachycardia: where do we stand? Eur. Heart J., July 1, 2004; 25(13): 1093 - 1099. [Abstract] [Full Text] [PDF]